[go: up one dir, main page]

AU2002330713A1 - Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin - Google Patents

Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin

Info

Publication number
AU2002330713A1
AU2002330713A1 AU2002330713A AU2002330713A AU2002330713A1 AU 2002330713 A1 AU2002330713 A1 AU 2002330713A1 AU 2002330713 A AU2002330713 A AU 2002330713A AU 2002330713 A AU2002330713 A AU 2002330713A AU 2002330713 A1 AU2002330713 A1 AU 2002330713A1
Authority
AU
Australia
Prior art keywords
neurogranin
diagnosis
treatment
methods
diseases associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002330713A
Inventor
Anne Ahlmann Nielsen
Finn Skou Pedersen
Annette Balle Soerensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarhus Universitet
Original Assignee
Aarhus Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/962,854 external-priority patent/US20030044803A1/en
Priority claimed from US09/962,916 external-priority patent/US20030077590A1/en
Priority claimed from US09/962,929 external-priority patent/US20020115058A1/en
Priority claimed from US09/963,131 external-priority patent/US20030224460A1/en
Application filed by Aarhus Universitet filed Critical Aarhus Universitet
Publication of AU2002330713A1 publication Critical patent/AU2002330713A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2002330713A 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin Abandoned AU2002330713A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US09/962,854 US20030044803A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US09/962,916 2001-09-24
US09/962,854 2001-09-24
US09/962,929 2001-09-24
US09/962,916 US20030077590A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
US09/962,929 US20020115058A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
US09/962,855 US20020164576A1 (en) 2000-09-22 2001-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
US09/963,131 US20030224460A1 (en) 2000-09-22 2001-09-24 Novel compositions and methods for lymphoma and leukemia
US09/963,131 2001-09-24
US09/962,855 2001-09-24
PCT/IB2002/004158 WO2003027321A2 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin

Publications (1)

Publication Number Publication Date
AU2002330713A1 true AU2002330713A1 (en) 2003-04-07

Family

ID=27542309

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2002364889A Abandoned AU2002364889A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of nrf2
AU2002330713A Abandoned AU2002330713A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
AU2002337442A Abandoned AU2002337442A1 (en) 2001-09-24 2002-09-24 Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
AU2002329000A Abandoned AU2002329000A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2002364889A Abandoned AU2002364889A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of nrf2

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2002337442A Abandoned AU2002337442A1 (en) 2001-09-24 2002-09-24 Novel compositions and methods for diagnosis and treatment of lymphoma and leukemia
AU2002329000A Abandoned AU2002329000A1 (en) 2001-09-24 2002-09-24 Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1

Country Status (2)

Country Link
AU (4) AU2002364889A1 (en)
WO (5) WO2003043565A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005879A2 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
EP1989320A4 (en) * 2006-02-14 2010-04-07 Harvard College GENES OF MITOTIC PROGRESSION AND METHODS FOR REGULATING MITOSIS
EP3980046A4 (en) * 2019-06-07 2023-04-19 Emory University KRAS G12V MUTANT BINDING TO JAK1, INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS RELATED

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ237669A (en) * 1990-04-13 1992-08-26 Res Dev Foundation T-cell proteins expressed in t-cell development and their preparation
US5821069A (en) * 1993-06-30 1998-10-13 Ludwig Institute For Cancer Research Method for determining tyrosine kinase in a sample
US6300058B1 (en) * 1992-01-29 2001-10-09 Hitachi Chemical Research Center, Inc. Method for measuring messenger RNA
AU6407696A (en) * 1995-07-07 1997-02-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of identifying inhibitors of the jak-stat signal transduction pathway
WO1998016557A1 (en) * 1996-10-11 1998-04-23 The General Hospital Corporation Assays for g-protein-linked receptors
WO1998020126A1 (en) * 1996-11-01 1998-05-14 Onyx Pharmaceuticals, Inc. Nucleotide sequences that encode phosphatidylinositol-3' kinase associated proteins and uses thereof
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
EP0988398A4 (en) * 1997-05-21 2005-05-18 Clontech Lab Inc NUCLEIC ACID ASSEMBLIES
JP2002519000A (en) * 1998-01-28 2002-07-02 カイロン コーポレイション Human genes and gene expression products II
EP1063887A1 (en) * 1998-02-23 2001-01-03 Quark Biotech, Inc. P53-dependent secretion of growth inhibitory factors
DE19817947A1 (en) * 1998-04-17 1999-10-28 Metagen Gesellschaft Fuer Genomforschung Mbh New nucleic acid sequences expressed in uterine myoma, and derived polypeptides, for treatment of uterine carcinoma and identification of therapeutic agents
KR20010042804A (en) * 1998-04-17 2001-05-25 파커 휴우즈 인스티튜트 Btk inhibitors and methods for their identification and use
WO1999065928A2 (en) * 1998-06-19 1999-12-23 Genzyme Corporation Polynucleotide population isolated from non-metastatic and metastatic breast tumor tissues
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
CA2358086A1 (en) * 1998-12-22 2000-06-29 Myriad Genetics, Inc. Protein-protein interactions in neurodegenerative disorders
US6110664A (en) * 1999-06-25 2000-08-29 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-S1 expression
GB9917165D0 (en) * 1999-07-22 1999-09-22 Knoll Ag Polypeptides polynuclcotides and uses thereof
ATE309241T1 (en) * 1999-09-10 2005-11-15 Merck & Co Inc TYROSINE KINASE INHIBITORS
AU2470101A (en) * 1999-10-25 2001-05-08 Affymetrix, Inc. Genetic sequences associated with neural cell proliferation and disease
AU1760201A (en) * 1999-11-12 2001-06-06 Fred Hutchinson Cancer Research Center Methods for treatment of human huntington's disease and methods of screening foractive agents
WO2001051670A2 (en) * 2000-01-07 2001-07-19 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
IL151079A0 (en) * 2000-02-07 2003-04-10 Quark Biotech Inc Fas pathway genes
US6518277B1 (en) * 2000-04-25 2003-02-11 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
CA2407573C (en) * 2000-04-27 2011-09-13 Yamanouchi Pharmaceutical Co. Ltd. Imidazopyridine derivatives
WO2001096390A2 (en) * 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US6794137B2 (en) * 2000-09-08 2004-09-21 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
WO2002020849A2 (en) * 2000-09-08 2002-03-14 New York University Gene markers useful for detecting skin damage in response to ultraviolet radiation
EP1362122A2 (en) * 2000-09-12 2003-11-19 TransGenetics Incorporated Microarrayed organization of transcription factor target genes
JP2004527220A (en) * 2000-09-13 2004-09-09 アルケミックス コーポレイション Target activated nucleic acid biosensor and method of using same
WO2002040637A2 (en) * 2000-11-20 2002-05-23 Isis Pharmaceuticals, Inc. Antisense modulation of pi3k p85 expression
WO2002059367A2 (en) * 2000-11-30 2002-08-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis
CA2436487A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
ATE429511T1 (en) * 2001-03-01 2009-05-15 Epigenomics Ag METHOD FOR DEVELOPING GENE SETS FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES BASED ON THE EXPRESSION AND METHYLATION STATUS OF THE GENES
CA2459219A1 (en) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
GB0122914D0 (en) * 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity

Also Published As

Publication number Publication date
WO2003027276A2 (en) 2003-04-03
WO2003043565A3 (en) 2003-11-13
WO2003027320A2 (en) 2003-04-03
WO2003027321A3 (en) 2003-11-06
WO2003027320A3 (en) 2003-10-23
AU2002329000A1 (en) 2003-04-07
WO2003027321A2 (en) 2003-04-03
AU2002364889A1 (en) 2003-06-10
WO2003043565A2 (en) 2003-05-30
AU2002364889A8 (en) 2003-06-10
AU2002337442A1 (en) 2003-04-07
WO2003027276A3 (en) 2004-02-12
WO2003027295A3 (en) 2003-10-16
WO2003027295A2 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2002327792A1 (en) Diagnosis and treatment of diseases caused by mutations in cd72
AU2002323258A1 (en) Diagnosis and treatment of vascular disease
AU2003293460A1 (en) Novel application of biosensors for diagnosis and treatment of disease
AU2003220096A1 (en) Methods for alzheimer's disease treatment and cognitive enhancement
AU2002367535A1 (en) Diagnosis and treatment of vascular disease
AU2003268531A1 (en) Materials and methods for treatment of allergic diseases
AU2003268295A1 (en) "diagnosis and treatment of infertility"
AU2003291536A1 (en) Method for the diagnosis and treatment of vascular disease
AU2002326813A1 (en) Diagnosis and treatment of vascular disease
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
AU2002341880A1 (en) Diagnosis and treatment of vascular disease
AU2002341604A1 (en) Diagnosis and treatment of vascular disease
AU2003256447A1 (en) Treatment of autoimmune skin diseases
AU2002330713A1 (en) Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2003263036A1 (en) SPAN-Xb GENE AND PROTEIN FOR THE DIAGNOSIS AND TREATMENT OF CANCER
AU2002319591A1 (en) Diagnosis and treatment of vascular disease
AU2002330715A1 (en) Methods for diagnosis and treatment of diseases associated with altered expression of jak1
AU2003297570A1 (en) Treatment of skin diseases
AU2002240745A1 (en) Diagnosis and treatment of blood disorders
AU2002313491A1 (en) Methods for diagnosis and treatment of diseases associated with altered expression of gnas
AU2003237742A1 (en) Composition for the treatment of skin diseases and for improving hair growth
AU2003201641A1 (en) Treatment and diagnosis of af4-dependant diseases
AU2003288127A1 (en) DIAGNOSTIC AND THERAPEUTIC USE OF H-Rev107 PROTEIN FOR ALZHEIMER DISEASE

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase